Brief: Hemostemix Signs License Agreement With Aspire Health Science
23/02/2018 13:00
Feb 23 (Reuters) - Hemostemix Inc HEM.V :
* HEMOSTEMIX SIGNS LICENSE AGREEMENT WITH ASPIRE HEALTH
SCIENCE
* HEMOSTEMIX INC - FINALIZED TERMS OF A LICENSE AGREEMENT
WITH
ASPIRE FOR CO'S LEAD THERAPEUTIC PRODUCT TECHNOLOGY, ACP-01
* HEMOSTEMIX INC - LICENSE AGREEMENT HAS INITIAL THREE YEAR
TERM,
WITH OPTIONS FOR CO TO RENEW FOR ADDITIONAL TWO YEAR EXTENSIONS
* HEMOSTEMIX-ASPIRE HAS EXCLUSIVE RIGHTS TO USE, SELL,
IMPORT
ACP-01 IN THE BAHAMAS, COSTA RICA, DOMINICAN REPUBLIC, MEXICO,
PANAMA AND STATE OF FLORIDA
Source text for Eikon: ID:nGNX85qgD2
Further company coverage: HEM.V
((Bangalore.newsroom@thomsonreuters.com;))
Recent news on Hemostemix
See all newsBrief: Hemostemix Announces Financing Update And Secured Convertible Debenture Financing Of Up To $2,000,000
Brief: Aspire Health Science Files Supplemental Motion For Expedited Hearing In Lawsuit Against Hemostemix Inc. And Suspends Patient Recruitment For Hemostemix Cli Phase 2 Clinical Trial
Brief: Aspire Health Sciences Says On Jan 28, 2020, Initiated Legal Proceeding Against Hemostemix Inc
Brief: Hemostemix Announces Private Placement
Brief: Hemostemix Announces Corporate Update